[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-435192-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-435192-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-american-psychiatric-association-practice-guideline-for-the-treatment-of-patients-with-schizophrenia-third-edition","The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia - Third Edition","","American Psychiatric Association practice guideline for treating patients with schizophrenia, third edition, providing structured recommendations for assessment, treatment planning, and implementation. The guideline presents an overview of the development process, including how guideline statements are rated and how supporting research evidence is assessed. It covers proper use of guidelines, summaries of guideline statements, and detailed guidance on key statements such as assessment of possible schizophrenia and use of quantitative measures.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-american-psychiatric-association-practice-guideline-for-the-treatment-of-patients-with-schizophrenia-third-edition/435192/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-american-psychiatric-association-practice-guideline-for-the-treatment-of-patients-with-schizophrenia-third-edition/435192.png","ImageObject",300,407,{"name":42,"@type":43},"Dipper","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the document’s purpose?","Question",{"text":63,"@type":64},"It provides a practice guideline for the treatment of patients with schizophrenia, including recommendations for assessment, treatment planning, and implementation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the guideline describe its development process?",{"text":68,"@type":64},"It includes an overview of the development process and explains how guideline statements’ strengths and supporting research evidence are rated.",{"name":70,"@type":61,"acceptedAnswer":71},"Which early topics are covered in the guideline contents?",{"text":72,"@type":64},"The contents list areas such as proper use of guidelines, guideline statement summary, and specific statements including assessment of possible schizophrenia and use of quantitative measures.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},435192,1790739615,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":4},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","THE AMERICAN PSYCHIATRIC ASSOCIATION  \nPRACTICE GUIDELINE  \nFOR THE  \nTreatment of Patients  \nWith Schizophrenia  \nT H I R D E D I T I O N  \nTHE AMERICAN PSYCHIATRIC ASSOCIATION PRACTICE GUIDELINE FOR THE Treatment  \nof Patients With Schizophrenia  \nTHIRD EDITION  \nGuideline Writing Group  \nGeorge A. Keepers, M.D. , Chair  \nLaura J. Fochtmann, M.D. , M.B.I. , Vice-Chair; Methodologist  \nJoan M. Anzia, M. D.  \nSheldon Benjamin, M. D.  \nJeffrey M. Lyness, M.D.  \nRamin Mojtabai, M.D.  \nMark Servis, M. D.  \nArt Walaszek, M. D.  \nPeter Buckley, M.D.  \nMark F. Lenzenweger, Ph.D.  \nAlexander S. Young, M.D. , M.S.H.S.  \nAmanda Degenhardt, M.D.  \nSystematic Review Group  \nLaura J. Fochtmann, M.D. , M.B.I. , Methodologist  \nSeung-Hee Hong  \nCommittee on Practice Guidelines  \nDaniel J. Anzia, M. D. , Chair  \nR. Scott Benson, M. D.  \nThomas J. Craig, M.D.  \nCatherine Crone, M. D.  \nAnnette L. Hanson, M. D.  \nJohn M. Oldham, M. D.  \nCarlos N. Pato, M. D. , Ph. D.  \nMichael J. Vergare, M.D.  \nJoel Yager, M.D. , Consultant  \nLaura J. Fochtmann, M. D. , M. B. I. , Consultant  \nAPA Assembly Liaisons  \nDaniel Dahl, M. D.  \nBhasker Dave, M. D.  \nEvan Eyler, M.D.  \nAnnette L. Hanson, M. D.  \nJason W. Hunziker, M. D.  \nMarvin Koss, M. D.  \nRobert M. McCarron, D.O.  \nJohn P. D. Shemo, M. D.  \nAPA wishes to acknowledge the contributions of APA staff and former staff (Jennifer Medicus, Seung-Hee Hong, Samantha Shugarman, Michelle Dirst, Kristin Kroeger Ptakowski) . APA also wishes to acknowledge the contribution of Amanda S. Eloma, Pharm.D., BCPP, in reviewing information related to medications in the guideline and associated tables. In addition, APA and the Guideline Writing Group especially thank Laura J. Fochtmann, M.D., M.B.I.; Seung-Hee Hong; and Jennifer Medicus for their outstanding work and effort in developing this guideline. APA also thanks the APA Committee on Practice Guidelines (Daniel J. Anzia, M.D., Chair), liaisons from the APA Assembly for their input and assistance, and APA Councils and others for providing feedback during the comment period.  \nThe authors have worked to ensure that all information in this book is accurate at the time of publication and consistent with general psychiatric and medical standards. As medical research and practice continue to advance, however, therapeutic standards may change. Moreover, specific situations may require a specific therapeutic response not included in this book. For these reasons and because human and mechanical errors sometimes occur, we recommend that readers follow the advice of physicians directly involved in their care or the care of a member of their family.  \nFor inquiries about permissions or licensing, please contact Permissions & Licensing, American Psychiatric Association Publishing, 800 Maine Avenue SW, Suite 900, Washington, DC 20024-2812 or submit inquiries on[line at: www.appi.org/Support/Customer-Information/Permissions](line at: www.appi.org/Support/Customer-Information/Permissions).  \nIf you wish to buy 50 or more copies of the same title, [please go to www.appi.org/specialdiscounts](please go to www.appi.org/specialdiscounts) for more information.  \nCopyright © 2021 American Psychiatric Association ALL RIGHTS RESERVED  \nThird Edition  \nManufactured in the United States of America on acid-free paper 24 23 22 21 20 5 4 3 2 1  \nAmerican Psychiatric Association  \n800 Maine Avenue SW Suite 900  \nWashington, DC 20024-2812 [www.appi.org](www.appi.org)  \nLibrary of Congress Cataloging-in-Publication Data  \nNames: American Psychiatric Association, author, issuing body.  \nTitle: The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia / Guideline Writing Group, Systematic Review Group, Committee on Practice Guidelines.  \nOther titles: Treatment of patients with schizophrenia  \nDescription: Third edition. | Washington, DC : American Psychiatric Association,[2021] | Preceded by: Practice guideline for the treatment of patients with sch","cbCaiiMleIUAmRtc","https://ap.wps.com/l/cbCaiiMleIUAmRtc","pdf",2893336,312,"English","# Acronyms/Abbreviations\n# Introduction\n# Rationale\n# Scope of Document\n# Overview of the Development Process\n# Rating the Strengths of Guideline Statements and Supporting Research Evidence\n# Proper Use of Guidelines\n# Guideline Statement Summary\n# Guideline Statements and Implementation\n## Assessment and Determination of Treatment Plan\n## Statement 1 : Assessment of Possible Schizophrenia\n## Implementation\n## Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement\n## Review of Available Guidelines From Other Organizations\n## Quality Measurement Considerations\n## Statement 2 : Use of Quantitative Measures\n## Implementation","[{\"question\":\"What is the document’s purpose?\",\"answer\":\"It provides a practice guideline for the treatment of patients with schizophrenia, including recommendations for assessment, treatment planning, and implementation.\"},{\"question\":\"How does the guideline describe its development process?\",\"answer\":\"It includes an overview of the development process and explains how guideline statements’ strengths and supporting research evidence are rated.\"},{\"question\":\"Which early topics are covered in the guideline contents?\",\"answer\":\"The contents list areas such as proper use of guidelines, guideline statement summary, and specific statements including assessment of possible schizophrenia and use of quantitative measures.\"}]","The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia - Third Edition | PDF",1790672280,786]